Chi-Med Files For Hong Kong Listing That Could Raise $500m
Chi-Med has applied to list in Hong Kong and will undertake a new global share offering as it looks to raise new funds to support the progress and commercialization of its growing pipeline.
You may also be interested in...
Public Company Edition: Turning Point's offering priced at $18 and its stock closed at $28.90. Also, Achaogen's bankruptcy reflects difficult antibacterial market, Ophthotech's name change follows strategy shift, and Gilead lays off 150 sales reps. Plus, cell and gene therapy FOPOs flourish.
In a busy week for new drug approvals in China, the NMPA hands out nods for anticancers Elunate and Lenvima, rare disease treatment Soliris, and an additional indication for Humira, with Elunate being hailed by developer Chi-Med as the first fully "Made in China" novel oncology drug to receive unconditional approval.
Novel antibody-drug conjugate receives approval in Japan for second-line breast cancer, providing another push to Japanese firm’s strategic plan to build up its oncology operations.